Researchers at Vanderbilt University Medical Center have relieved symptoms in a mouse model of Rett syndrome with a drug-like compound that works like the dimmer switch in an electrical circuit.
The finding, reported this week in the journal Human Molecular Genetics, suggests a potential new way to treat the rare neurodevelopmental disorder, which occurs predominantly in females, as well as more common forms of autism spectrum disorder.
Further study is needed before this approach can be tested in patients, but animal work from other groups suggests that symptoms in Rett syndrome are reversible, said senior author Colleen Niswender, Ph.D., associate professor of Pharmacology and director of Molecular Pharmacology in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD).
Rett syndrome patients exhibit a constellation of symptoms, including verbal and nonverbal communication deficits, difficulty walking, progressive developmental regression, epilepsy and intellectual disability. The hallmark symptom is repetitive hand movements such as wringing, washing, clapping or tapping.
Most cases of Rett syndrome occur spontaneously from random mutations in the MECP2 gene, which results in disruptions in neurotransmission, including signals mediated by the excitatory transmitter glutamate. A related genetic disorder, termed MECP2 Duplication syndrome, results from overexpression of the MeCP2 protein and is found predominantly in young boys.
The researchers used a mouse model in which MECP2 was “knocked out,” resulting in Rett syndrome-like symptoms. Expression of the metabotropic glutamate receptor 5 (mGlu5), which is important in transmitting nerve signals in the brain, was reduced in brain areas of these mice.
The investigators also found reduced levels of mGlu5 expression in autopsy samples from the brains of Rett syndrome patients, suggesting that the animal work may translate to the clinical population.
They then tested a compound, developed at Vanderbilt, called a positive allosteric modulator or PAM that, like a dimmer switch, “turns up” the activity of mGlu5 when glutamate binds to it.
Animals treated with the compound showed improved motor performance and reduced Rett syndrome-like symptoms, including repetitive clasping of their hind claws.
Previous studies have suggested that enhancing excitatory neurotransmission may increase an already high risk of seizures in Rett patients, but in the current study, seizure occurrence did not increase, even after multiple weeks of chronic dosing with the PAM.
This may be because the compound acts on only a subset of mGlu5-mediated signaling pathways, leaving others unaffected.
“Our work demonstrates that potentiating the activity of mGlu5 can rescue several deficits commonly found in mouse models of Rett syndrome,” said the paper’s first author, Rocco Gogliotti, Ph.D., a postdoctoral fellow in the VCNDD.
“Importantly, by integrating recent advancements in mGlu5 pharmacology into the drug development process, we were able to test the efficacy of our novel compound in a mouse model without observing negative side effects, such as seizures, that have been historically associated with this target,” he said.
Disease progression – and mGlu5 expression – change through time in MeCP2-deficient mice. “A very careful dissection of the time course of the disease is required before modulators of excitatory transmission can be advanced to clinical studies,” Niswender said.
“It may be that early stages of Rett syndrome will need to be treated differently than late-stage disease,” she said.
Learn more: Study reveals possible ‘dimmer switch’ drug for Rett syndrome
The Latest on: Rett syndrome
[google_news title=”” keyword=”Rett syndrome” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcripton May 9, 2024 at 8:29 am
The remaining three-quarters of diagnosed patients and those not yet diagnosed represent a very large opportunity to continue to grow this drug and reach families not yet benefiting from the only drug ...
- Anavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Updateon May 9, 2024 at 5:11 am
Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmace ...
- Neurogene reports initial data from Rett syndrome gene therapy trialon May 8, 2024 at 6:09 am
Neurogene has shared initial safety and tolerability results from its ongoing Phase I/II clinical trial of NGN-401, a gene therapy candidate for Rett syndrome. The open-label study is focused on ...
- Neuropathology of Rett Syndromeon May 7, 2024 at 5:00 pm
J Child Neurol. 2005;20(9):747-753. On the basis of these observations, and the fact that the child with Rett syndrome has a deceleration in growth of the head circumference during the time that ...
- Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meetingon May 7, 2024 at 10:13 am
NGN-401 has been generally well-tolerated by first three patients dosed, with three to nine months of follow-up ...
- Rett syndrome: the genetic disorder almost exclusively targeting girlson May 7, 2024 at 9:00 am
If you haven't heard of Rett syndrome, it's probably because it's very rare. Affecting an estimated one in 12,000 baby girls born each year (and only rarely seen in boys), this genetic disorder causes ...
- Neurotech reports more positive Phase 1/2 Rett Syndrome clinical trial resultson May 6, 2024 at 12:10 pm
Neurotech International (ASX:NTI) shows significant benefits in Rett Syndrome girls after 12 weeks of daily oral treatment with NTI164.
- New findings activate a better understanding of Rett syndrome's causeson May 2, 2024 at 6:29 am
Rett syndrome is a rare neurodevelopmental disorder for which there is currently no cure or good therapy. It causes severe physical and cognitive symptoms, including many that overlap with autism ...
- Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndromeon May 2, 2024 at 5:00 am
RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and ...
- Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarshipon April 29, 2024 at 9:16 am
was established in 2023 to recognize the siblings of individuals with Rett syndrome. This year’s recipients will each receive $5,000 to pursue their goals in higher education for the 2024-25 academic ...
via Google News and Bing News